Polymerase chain reaction allelotyping of human ovarian cancer. by Osborne, R. J. & Leech, V.
Br. J. Cancer (1994), 69, 429-438 © Macmillan Press Ltd., 1994
Polymerase chain reaction allelotyping of human ovarian cancer
R.J. Osborne & V. Leech
Cancer Research Campaign Department ofClinical Oncology, University ofCambridge School ofClinical Medicine,
Addenbrooke's Hospital, Cambridge CB2 2QQ, UK.
Summary We have used a set ofmicrosatellite polymorphisms (MSPs) to examine the location and frequency
of allele loss throughout the genome in a panel of 25 human epithelial ovarian tumours. When more than one
MSP was employed per arm, mean informativity was 85.2% (range 64-100%). The average fractional allelic
loss was 0.28 (range 0-0.65). A high frequency of allele loss was seen at Sq (40%), 9q (48%), 1lp (43%), 14q
(46%), 15q (40%), 17p (61%), 17q (64%), l9p (45%) and Xp (40%), confirming previous findings at some
sites, but also suggesting the existence of new tumour-suppressor genes in regions (9q, 14q, 15q) which have
not previously been studied in ovarian cancer. For 9q and 14q, partial loss of the arm was more common than
loss of heterozygosity for all loci. There was a significant relationship between allele loss affecting the short
arm of chromosome 17 and allele loss affecting 17q (P<0.001). No other relationship was detected between
allele losses at different sites. Polymerase chain reaction allelotyping is suitable for the examination of very
small tumour samples and tumours in which classical karyotyping is problematic.
In the presence of a mutated tumour-suppressor gene, loss of
the normal homologue unmasks the defective gene and
allows unopposed dysfunction. A variety of mechanisms,
including whole homologue loss, mitotic recombination and
deletion, may result in loss of the normal gene. These varied
phenomena may be manifested by loss of heterozygosity
(LOH) at one allele of a heterozygous locus. The term 'dele-
tion' is often used where LOH is observed, regardless of the
underlying mechanism. In ovarian cancer, several
chromosome regions (3p, 6p, 6q, lIp, lq, 13q, 17p, 17q,
Xp) have been reported to be frequently affected by allele
loss (Ehlen & Dubeau, 1990; Okamoto et al., 1991; Zheng et
al., 1991; Eccles et al., 1992; Gallion et al., 1992; Jones &
Nakamura, 1992; Saito et al., 1992; Viel et al., 1992; Yang-
Feng et al., 1992; Jacobs et al., 1993; Foulkes et al., 1993a,
b). In most sites, the genes involved are not yet characterised,
though the high rate of deletion implies the presence of
tumour-suppressor genes of considerable importance.
Studies of tumour progression in colonic neoplasia
(Vogelstein et al., 1988) suggest that the accumulation of
genetic lesions may occur in a relatively consistent and
ordered manner, with correlations between particular lesions
and phenotypic and clinical parameters. In ovarian cancer,
individual studies which have defined frequently deleted
regions have also included assessments of clinical or
pathological relationships (Zheng et al., 1991; Gallion et al.,
1992; Viel et al., 1992; Foulkes et al., 1993a). However,
because of the wide range of lesions which occur, this app-
roach has not provided a clear insight into the disease pro-
cess. Previous studies of limited numbers of regions have also
failed to assess the total number of genetic lesions, another
important factor in tumour phenotype (Vogelstein et al.,
1988).
Ideally, analysis of all relevant loci is required for a valid
assessment of the relationship between genotype and
phenotype. For tumour-suppressor genes (known and
putative) this can be achieved in two ways: by direct
visualisation of chromosomes and by allele loss studies which
involve every arm of every chromosome ('allelotyping').
Although conventional karyotyping has provided pointers to
regions where deletions are frequent (Whang-Peng et al.,
1984; Pejovic et al., 1989), it has not been applied to
sufficient tumours for conclusions to be drawn about tumor
progression or other clinical features. Allelotyping using
restriction fragment length polymorphisms (RFLPs) (Sato et
al., 1991; Cliby et al., 1993) is limited by the low infor-
mativity of many loci, the limited number of RFLPs
Correspondence: R.J. Osborne
Received 19 August 1993; and in revised form 13 October 1993.
available and the requirement for relatively large amounts of
tumour DNA. The recent development of large numbers of
highly informative, well-distributed microsatellite polymor-
phisms (MSPs) (Todd, 1992) may allow a more comprehen-
sive allelotype to be rapidly performed, using very small
samples if necessary. We have used MSPs spanning every
arm of every chromosome (excluding the short arms of the
acrocentric chromosomes) to examine 25 paired ovarian
tumour-blood lymphocyte DNA samples. We report on the
feasibility of this approach, and the abnormalities detected.
Materials and methods
Tumours
Twenty-five malignant epithelial ovarian tumours were
studied. Samples comprised either surgically resected solid
masses or ascites cells. Tumour masses were frozen at - 70°C
before use. Ascites cells and lymphocytes were processed
Table I Patient details: tumour histology, grade, stage and
origin
Tumour no. FIGO stage Histology Grade Tumour origin
3 III Serous WD Primary
8 IV Serous NS Ascites
10 III Serous NS Ascites
11 II Serous PD Primary
12 1 Serous MD Ascites
13 III Serous PD Primary
16 III Adenocarcinoma PD Primary
19 III Serous PD Primary
20 I Serous NS Primary
21 IV Serous PD Primary
23 III Mucinous MD Ascites
39 II Serous PD Primary
40 III Clear cell MD Primary
41 NS Adenocarcinoma PD Primary
44 III Endometroid PD Primary
45 III Serous PD Ascites
47 III Serous NS Primary
48 III Mucinous MD Primary
49 III Adenocarcinoma PD Primary
51 III Serous PD Primary
52 III Adenocarcinoma PD Ascites
54 III Endometroid PD Ascites
55 III Adenocarcinoma PD Ascites
56 III Serous MD Ascites
62 III Serous NS Ascites
Abbreviations: WD, well differentiated. MD, moderately
differentiated. PD, poorly differentiated. NS, not specified.
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Table I Microsatellite polymorphisms: identity, location and primer sequences
Reference, sequence
G 1990-7-97
AJHG 1989-44-388
NAR 1990-18-2199
HMG 1992-1-137
NAR 1991-19-1718
NAR 1990-18-2200
NAR 1991-19-4792
NAR 1990-18-4635
NAR 1990-18-4636
AJHG 1991-49-621
G 1992-14-209
NAR 1990-18-2202
NAR 1991-19-5794
NAR 1990-18-4035
NAR 1991-19-6348
NAR 1991-19-4306
NAR 1991-19-1171
NAR 1991-19-6969
NAR 1990-18-4636
HMG 1992-1-135
NAR 1991-19-5798
AJHG 1991-49-1256
CCG 1991-58-1932
NAR 1991-19-6664
NAR 1991-19-969
NAR 1991-19-5093
G 1992-12-607
HG 1990-85-98
NAR 1991-19-967
NAR 1990-18-7472
G 1992-12-229
NAR 1990-18-4637
G 1992-12-604
NAR 1992-20-1431
G 1992-13-622
NAR 1990-18-4036
NAR 1991-19-4308
MFD 108
NAR 1990-18-4957
MFD109
Reference, locus
PNAS 1983-80-6932
AJHG 1989-44-388
S 1992-258-67
HMG 1992-1-137
I 1989-30-393
S 1992-258-67
CCG 1989-52-68
S 1992-258-67
G 1992-14-209
AJHG 1991-49-621
G 1992-14-209
G 1992-14-209
NAR 1991-19-5794
CCG 1991-58-284
AJHG 1988-43-638
CCG 1988-48-25
S 1992-258-67
CCG 1985-40-696
CCG 1991-58-323
G 1991-11-737
S 1989-245-1059
S 1989-245-1059
CCG 1993-63-45
S 1992-258-67
N 1990-344-36
NAR 1991-19-5093
G 1992-12-607
G 1992-14-715
G 1992-14-715
G 1992-14-715
G 1992-14-715
G 1992-12-604
G 1992-12-604
NAR 1992-20-1431
S 1992-258-67
S 1992-258-67
NAR 1991-19-4308
S 1992-258-67
S 1985-228-1401
S 1992-258-67
Sequence
AAACCTCTGGCAGTGTAC AC
TAT TIA CTG TCC TTA TTT ATG TGG G
CTGGATAaCCTTTGGGGAGG
TTGCCCTGAGACTTACTTGGC
ACGAACATTCTACAAGTTAC
ITTTCAGAGAAACTGACCTGT
CACTAGCACCCA GAACCGTC
CCT TGT CAG CGT TTA TTT GCC
ACTGCCTCATCCAGTTTCAG
IGAGCAGGCACUTGTTAGATG
AGC TATAATTGC ATC ATTGCA
ITGG TCT ATA ACTGGTCTATG
GGGCAACATGGTGAAACCITU
ICCTAGCCTATACTTCCTTUC
ACT CTT TGT TGA ATT CCC AT
TTTCCACTG GGGAAC ATGGT
AAGAACCATGCGATACGACT
ICATUCCTAGATGGGTAAAGC
GCTCATTAAACACTGTGTUCCT
ITGATAGCTAGAAAGCTAGCAAG
ATC TCT GTT CCC TCC CTG TT
CUT ATTGGCCTTGAAGGTAG
TGGGTAAAGAGTGAGGCTG
GGTCCAGTAAGAGGACAGT
|AAG&G1~AGGCAAAATGAGTGTA1 ICAATCAGGCCATTTTTAACTTCA
[TGTCTCCI(GCTGAOAATAO
|TAATATCCAAACCACAAAGGT
ACTCACTCTAGTGATAAATCWGG
|AGCAGATAAGACAAGTATUACTA.TT
GAGGTTGCACTCCAGCCITTT
ATGCCATGCAGATUAGAAA
CACrTGGGCAATAAGAGOG
ICCCCTCTTCATCCTCCCUTTCA
IATCAATGGAAAAATGGGTAAI ITATCTTTCTCTGTCTGCCTTI
ACAGAGTGAGACOGTGTAAC
|AGAGAAGCATCTCACTTAGT
GTTTGAAGAATUTGAGCCAACC
TTC TTC TGC ACA CTTGGC AC
GAC GTG CTA GCC TGG TCTCCAGCTCT
IGATGG0 GGAGGCGGTTGTAGTTTTCAA
GCTGCA TUC TAT AGGTTA TC
TGTGAAAAC AGO GAT AAT AC
ATCTGC CTC TGC AGC TCT CA
ATTCTGGTATGAATGTAC ATGTG
GCTAATCAGGGAATCACCCAA
AAATACCGAGACTCACACTATA
CACAGCUCAGAAGTCACAG
TCCCAGATCGCTCTACATGA
GATCAAGOAGCATCACATCT
TAACATGTCCCCTCATTTGG _
GAAAGTCCAGAACTAAGTAG
TGTGGATAGGTATATATAGC
TAA AGATUGGGAGTCAAGTA
TTC ACT TGA TGGTGO TAATC
CAGCCAGCTTTGGAGACAAC
TCGCAAGCATATGACTGTAA
IGGGAGCrATAAAAATGACCA I
|TrAGGTCCGAAAACACAAAGI
GAAGG0 CTCTTTATTAACTGA T
AACCrGGGCGACACAGCA A
AACACT AGTGAC ATU ATU TUCA
AGCTAGGCCTGA AGGCTTCT
CCAAAGTGCTGA ATTTCAGG
GAA AAGTCTTAG AATTTrGCA G
GCCCACTTUCAGATTCCTGCT
GCAGGGAGAAGGACTATGCAT
GCT GAT TTT TCC TGC TGGTC
TGT TTC TGA AGC ATT TTC CTT G
|AGG GCr TCC TGT CCATCT A
|CTC ATT TGA AGA CTG CAGCAI
ATATGG AAA CTCTCCGTA CT
GCAACCATGGAGAGTCrGGA
GCCTCTrGAA GTG GCT AAA TA
CCCCTC ACC ACA TCACTTG_
ITOT ACC TAG UrA TCT ATC CTG
OTO ATO ATO ATO GAO ACA GAO
GACACAGAGAAGGCAAATAG
TCCCAT ATCCrATGT AGA AG
Chromosome
arm
lp
lq
lq
2p
2p
2q
3q
3q
4p
4p
4q
D number
AMY2B
APOA2
DIS103
TPO
CD8A
D2S72
ACPP
D3S196
D4S174
GABARBI
D4S175
D4S171
D5S268
D5SS17
D5S346
F13A1
D6S109
FTHP1
D6S87
EGFR
D7S23
CFTR
LPL
D8S135
ANKI
D8S161
D9S54
Location
lp2l
1q21-q23
lq32-q44
2p23-pter
2pl2
2q
3q21-qter
3q
4p1-p15
4pl2-pl3
4q25-34
4q35-qter
5p
5p15.l- 15.3
5q21-q22
6p24-p25
6p21.3-p24
6pl2-p21.3
6q23.1
7pl1.2-pl2
7q31
7q31
8p22
8p
8pIl .1-p21.1
8q22-qter
9p22-pter
9ql3-q21.1
9q33
9q34.1
9q34-qter
lOpl1.2-pter
lopl1.2-pter
lop
10q
Ilpl3-pl5.1
1lql3
llq
12pl2-pter
12q
4q
5p
5p
5q
6p
6p
6p
6q
7p
7q
7q
8p
8p
8p
8q
9p
9q
9q
9q
9q
lOp
lop
lop
lOq
llp
llq
llq
12p
12q
D9S15
GSN
ASS
D9S64
DIOS89
DlOSI 11
DlOS179
DIOS173
D1 S419
DllS534
DlIS836
F8VWF
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Table H - cont. Choosm
Reference, sequence
NAR 1991-19-2803
G 1992-13-622
NAR1990-18-4638
G 1992-13-532
G 1992-13-532
G 1992-13-532
G 1992-13-532
NAR 1991-19-4018
G 1992-13-402
NAR 1990-18-4034
MFD 144
GCC 1992-5-89
NAR 1990-18-4640
CR 1993-53-1218
G 1993-15-48
NAR 1990-18-6465
CCG 1991-58-1190
NAR 1990-18-1927
NAR 1990-18-2202
G 1992-12-183
G 1992-12-183
NAR 1990-18-4969
HG 1991-87-401
NAR 1990-18-4967
NAR 1990-18-4639
HMG 1992-1-6
NAR 1991-19-1161
NAR 1990-18-4037
Reference, locus
0 1990-5-519
S1992-258-67
MFD 42
S 1992-258-67
S 1992-258-67
S 1992-258-67
S 1992-258-67
CCG 1993-63-33
G 1992-13-402
S 1992-258-67
CCG 1991-58-728
N 1986-320-84
NAR 1990-18-4640
CR 1993-53-1218
G 1993-15-48
G 1993-15-48
S 1992-258-67
S 1992-258-67
S 1992-258-67
G 1992-12-183
G 1992-12-183
NAR 1990-18-4969
HG 1991-87-401
NAR 1990-18-4967
S 1992-258-67
HG 1989-84-6
AJHG 1990-46-776
S 1992-258-67
Sequences
TTCTGGCCGACAGTGGTGTAA
|AGGACC.4AACCATGTCTGTC
TGT AAGGAG AGAGAG ATTTCGACA
TCTTAGCTGCTGGTG GTG G
GGCCTC AAAGAA TCCTACAG
GAC ACGTAGTG CTTATTAC
ATGAUCCA CAAGATGGCAG
AAC ACC CCT AAT TCA CCA CT
TCT ACA AAA AGT CAG ATACCT
GAATCT TAA GTA GTTATCCCTC
GAT TCTGCA CCCCTA AATCC
ATGCTC AAT GAA CAGCCTGA
CAA AAC AGA GAACAGAGTAG
CAT AAA AGGCT ATTGGTTTG
GGA AGATGG AGTGGCTGTTA
CTCCAG CCTGGCGAA AGAAT
GGCATGTCAGGCCAGCCATGUTTTT
|C-I-1-GCACAAAAACAGTAGCTATCCAC
CCA GAC ATGGCA GTCTCT A
AGT CCT CTG TGC ACT TTG T
GGAGAAAGTGATACAAGGGA
TAGTTAGATTAATACCCACC
AGG GAT ACTATTCAG CCCGAG GTG
ACTGCC ACT CCT TGC CCCAUT C
GGA AGA ATC AAATAG ACA AT
GCTGGCCATATATATATTTAA ACC
CCTGGT CTAGGA AGAGTGTCA
GTGTAAGCA TCT GTG TAT ACT AC
CAA GAT AGATGCATTTTC CAG T
CATCCA AAGGGTGAA TGTGT
AGCTAG ATTTTT ACT TCT CTG
CTGGTT GTA CATGCC TGA C
TCAGAGGTTGAGGCTGAAG
CAA TGACTTCAAGCA CTA AG
ACTCAT GAAGGTGAC AGTTC
IGTGTGTTG ACC TATTGC AT
TTU ATG CGAGCG TATGGA TA
CACCACCATTGATCTGGAAG
TGA CCAGGTGTG ACA AGATG
UT AACCTTTGG GAT TGT TUC
TATGGTGGG AAG TCCAGCATU G
AGGAGGAGGGAGACCCCAGG
GTG TGT CTG CCA UT CTG GGT GTA G
GATCCTGGGACA AAG TAGTCT CTAA
TAGGCCCTACTG CAA TAA TG
CTTTATCTT CAC ACAGCT TC
TCCTTC CAT GTA CTC TGC A
TGCCCTGAAGCACATGTGT
AGCCTGGGAGTCAGAGTG A
AGCTCC AAATCCAAAGACGT
GGTTTT CTG TCA TTCTTG TTG A
AGTGAGTGGAGATTGCATTG
CTGATTCACTGT ACAATG GT
ATGGATAATAAACAGACAGGA
AGA AGACATAAGGATACTGC
GAT CCC AAC TAT TTC UTT CT
MSPs are listed by their official locus name ('D number'), chromosomal location and oligonucleotide primer sequences. References relate to
the published details of the sequence and location of each MSP. Journal abbreviations are listed below.
Journal abbreviations: AJHG, American Journal ofHuman Genetics; C, Cell; CCG, Cytogenetics and Cell Genetics; CGC, Cancer Genetics and
Cytogenetics; CR, Cancer Research; G, Genomics; GCC, Genes, Chromosomes and Cancer; HG, Human Genetics; HMG, Human Molecular
Genetics; I, Immunogenetics; MFD, Marshfield Markers Release 10-7/1/93 (J. Weber, personal communication); N, Nature; NAR, Nucleic Acids Research; 0, Oncogene; PNAS, Proceedings of the National Academy of Sciences of the USA; S, Science.
fresh. Histological type, grade, clinical stage and origin of the
tumours are detailed in Table I.
DNA preparation
Ten micron haematoxylin and eosin-stained frozen sections
were examined to identify regions of tumour which were free
from significant contamination with normal tissue. Two to
ten further 10 gm sections were cut, and where necessary
normal tissue was scraped away. No tumour sample con-
tained more than 40% normal tissue. The sections were
digested with proteinase K at 55°C in polymerase chain
reaction (PCR) buffer for 1 h then boiled for Omin. The
resulting solution was used directly in the PCR reaction
without further purification. Cytospin examination of ascites
cells was performed, and only samples comprising greater
than 60% tumour were used. Cells from 1 ml of fluid were
added to a buffer containing detergents which lysed cytoplas-
mic membranes (Higuchi, 1989). The nuclei were pelleted and
washed, then the nuclear membranes were digested in 1 ml of
PCR buffer. Normal DNA was derived from the lymphocytes
in 1 ml of whole blood, treated in the same way as ascites.
An aliquot of the resulting solution was used directly in the
PCR reaction without further purification.
Oligonucleotides
Oligonucleotides were obtained from the HGMP Resource
Centre (Harrow, UK), or were synthesised locally. They were
selected on the basis of their high informativeness, accurate
Chromosome
arm
13q
13q
14q
14q
14q
14q
14q
15q
16p
16q
17p
17p
17q
17q
18p
18q
l9p
19q
20p
20q
20q
21q
21q
21q
22q
22q
Xp
Xq
D number
FLT-1
D13S115
D14S34
D14S50
D14S49
D14S51
D14S48
FES
D16S292
D16S265
D17S520
TP53
D17S250
D17S588
D18S40
D18S35
D19S177
D19S49
D20S27
D20S54
D20S46
D21S120
D21S171
D21S167
D22S156
TOPIP2
DXS538
DXS454
Location
13ql2
13q
14q
14q
14q
14q
14q
15q26.1
l6pl3
16q21
17pl2
17pl3.1
17ql1.2-ql2
17ql2-q21
18p1 1.21-pter
18q21.2-21.3
19p13.3
l9q12
20pl2
20q
20q
21ql1.2
21q22.3-qter
21q22.3
22q
22ql1.2-13.1
Xpl1.21-21.1
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Table III Results for all loci
__ ___ f ~ ~ ~~TUJMOUIR1S~
2 TUMOURNUMBER--> 3 18 110111 12 13 16 19 20 21 23 39 40 41 44145147 48 49 51 52 5 55 56 62-_ ___
- ____ _______ --1- I ~~~~~~~~~~~~~~~~~~~~~~~~~~~~ ~ LOCUS ARM ARM
Arm Locus Lmocation i LH%O IN
1 ip AMY2B 1p21 0 010 0 o j 0 0 01l iol oh0 or j 19 19 64
lq *APOA2 1q21-q23 - 0 0 0010 0 00 0 2 ooj. * 01 22 j23 88
__iq DlS103 1q32-q44 0 * 0 0 0 0 0 0 0 0 0 0 0 0 * 01 13 li
22p TPO) 2p23-pter 0 0 _01 0 0 0200 0 0 14 1[7[92 __2pCD8A j2p12 jOi' 0 0 0 0 010 0 010 0 * o oh .~01 0 0 115
12 2q D2S72 2q olSoS @1000 1 0 10 0 0 0 0 0 38 38 64
33p#THRB 3p24 0o .0.0100 01 *J 00 oo 0 00 29 _
3p#D3S15S2 3p21 - 0 _ o 0o 00 0IO 0 17 26 92
j_3p#D3S30 j3pl13-pl14 0 iO 1 1 I0I 1 - o - -
3q *ACPP 3q21-qter 0 * 0 0 0 0 - 0 31 32 88
3q D3S196 3q 1 0 ** * * 0 0 0 *0 26
___ ____I_______~~~~ __ 0~ 0L000 10 0 *OO 0OOeOOj 1518 8
4 4p D4S174 4pl11-pl15 0 0
__ 0 0 * 0 {0
00000 0000 1 18 8
4p *GABRB1 4p12-p13 0 0 ot0 0 *, ~ 10 0 0 0 0 0l 13 __j
4q D4S175 4p25-q34 10 0 *
0 j 0 0 j0 0 0 0 0 0 0 J * 0ol 35 33 96
14q D4S171 4q35-qter I ** 0 0 0 0 0 00 0 000 0*oo0 25 -
5 5p D5S268 5p j * 00. 1.0 0 0 0 0 0 110 00 21 19 84
5p DS17 15p15.1-15.3 J oj ol1J. 10 L0 0 ~1 10 01 15 __
5q MM34 5q21-q22 0 10 0 ~ 0 *10 0 01..*0 * 0140140160
6 6p F13A1 6p24-25 __ * j @001 0 0 0_ 0.0OOJj 00 0122
6p *D6S109 6p2l.3-p24 0 * *0 02 *0 0 0 o10 0 0oo 0 01 0 01 18 112]I88
6p FTHP1 j6pl12-p2l.3 I_ 0 * 07 * ** oO to 0 - 6L
6q[D6S87 1623.1 0 0 0 0 0 0 . 0 0 * * 0 I00 0 1- IIol0 1-l 35 35 6
7 3F 17pl 1.2-pl2 0 ±: IohI I____o 1oLh:1LoL LI.L Lo2tol10 ~17j17jj7
17q JD7S23 ~7q31 TO 10 0 0 ello ofolooo 9 19 64
__7q CFTR f7q31 10 :0o. 0 0 *0 -0 1 0 22 j
8 8p~LPL 8p22 0 0 -0--0 0. _29~
18p D8S135 8p je 0 0 0 _ 0 0 00 0 01 25 26 76
8p jANKi 18p11.2 j L 101 101 0 0iI0 001 0 0
__8q 1D8S161 ~8q22-qter lellool J .01 olo [.[ojjo[o 0 ] 010101 126 126] 76
9 9p 1D9S54 ~9p22-pter 101 * ~ _ 11 01.1011IlL 101.0130130] 40
9q D9S15 9ql3-q2l.l 0 * 0 * 0 * 0 0 * 0 0 0 * 0 36
9q GSN 9q33 *0 * 0 0 * 0 0 *0 0 0 0.0 39 48 100
9q ASS 9q34.1 0. 0 0 * 0 0 0 0 *t 0 0 00 0 * * 0 37
19 9q D9S64 9q34-qter * 01 1** 0 00 0 .0 00 0 * 0 0 47
10 lop Dl0S89 10pll.2-pter 0 0 0 0 0 0 0 0 0 0 0 0 J 0 0 __ _
lop DlOS111 lOpll1.2-pter __ 0 0 0 0 0 0 0 _ 0 0 20 0 0 22 92
l1Oq D10S173 lOp 0 00 0 * 0 0000 0 0 00bo.ojso2 19
lpDloS4193 1o H
l3p . 10101 olo 1101 1 l0N 1J~
Ii li DlY11iS534 11rq13i.1 0 0 * ** 0 Al0 0 * I 31 30dl
localisation and even distribution. The loci and chromosmal
regions examined and their corresponding oligonucleotides
are detailed in Table II.
PCR
A 50 -200 ng aliquot of genomic DNA (1 jil of solution
described above) was amplified in a reaction volume of
12.5fil as previously described (Jacobs et al., 1993). For all
reactions except those indicated with an asterisk in Table II,
PCR consisted of 1 min at 950C, 2mmn at 55*C and 2 min at
72*C for 30 cycles followed by a final extension for 10 min at
72*C. After chloroform extraction, PCR products were pro-
cessed and analysed as previously described (Jacobs et al.,
1993). For chromosome 3p an RFLP-PCR technique (Ganly
et al., 1992) was used to examine five polymorphisms at thePCR ALLELOTYPING OF HUMAN OVARIAN CANCER 433
Table III - cont.
16 _16_ _D16S292_ 16p13_______ oj .i.
-4
16q D16S265 16q21 10 _ 0 1 0 o * T o o 0 0 0 0 00 161 16 76_
17 17p D17S520 17p12 10 * 0 0 * 0 Ot 0 * * 0 * 0 * 58 161 92
117p ITP53 117p13.1 10 * 0 * * 010 * * 01I * 0 ** 67
l1q D1S250 17qll.2-ql24@*{ 0 *0 0 0 0 * 0 * 64 11641 88
l7 D7S588 17ql2-q2lj0 *i 0 0 * 0 0 * 55~1 i
18 lap ID18S40 118p11.21-pter o 01 I0 I0 ol 0 10 0 00] 01010 11 0 0 1 0OJO j 6 jj6 ]j72
__iq D18S35 18q2l.2-q2l.3 0 ]O1OL0 I]I:1oLI L .oool ].[. 27 127 jI60
19 l9P Dl9S177 19213.! 45oI L I.loo .0 1..LL ..LLL 45!
lgqJDl9S49771VV71 ] 0B 0 o1 To0 07 ] 23 23 52
20 [Lop D2 S27 2pl2joJ bE j ]O 0 L Jo o 00 21 jj21 jj56
20q* D20S54 20q 0 0 0 0 00 0 00 0 0 0 0 10 * 7 21 76
20q* D20S46 20q 0 0 0oo 0 0 0 00 0 0 *21
21 21q D21SI20 21q11.2 0 * 0 * 0 0 0 0 0 0 * 33__
21q D21S171 21q22.3-qter 0 *0 0 0 00 0 0 0 *0 23 33 84i
__21q D21S167 21q22.3 * 0 * 0 0 * *I00 0 * 54
22 22q D22S156 22q 0 * 0 0 0 0 0 0 ---30 28 72-
__22q ITOPIP2 22q11.2-ql13.1 0 * 0 0 0 0 0 0 0 10 0 *0 10 * 29
X Xp IDXS538 Xpll1.21-p21.1 0 _ 0 0 * 0 0 0 * 0 0 LL * * * 0 40 40 60 __Xq IDXS454 x)q I1 1 1-I010101 1I1 VLFi 0 hob V77V11 11- 1K 2ZLI 2[ 56
Allelotyping results for all tumours at all loci are presented. The symbols used are explained in the key below. The percentage loss of
heterozygosity (LOH) at each locus and for each chromosomal arm has been calculated and is listed, with the percentage informativity of each
locus, in the three columns at the right of the table.
Key: 0, retained heterozygosity; 0, loss of heterozygosity; Blank, non-informative or failed. *Refer to original paper for PCR conditions;
#RFLP-PCR (Osborne et al., 1992).
THRB locus and two other proximal loci. Allele loss was
assessed visually, and was scored when a clear reduction in
intensity of one of the alleles was observed.
Statisticalanalysis
Fisher's exact test was used to determine whether a relation-
ship existed between allele loss at different chromosomal
sites.
Results
PCR allelotyping of the tumour panel was relatively rapid
and easy. Examination of a single locus, involving 50 samples
plus controls, was completed within one working day (exc-
luding autoradiography). Results for all tumours at all loci
are shown in Table III. Table IV comprises a summary of
these results analysed by chromosomal arm. Figure 1 sum-
marises the percentage allele loss at each chromosomal arm.
Informativeness for individual MSPs ranged between 20%
and 88% (mean 59.1%). However, when more than one MSP
was employed per arm, informativeness increased to a mean
of 85.2% (range 64-100%).
Interpretation of results was facilitated by the use of
tumours in which contamination with normal tissue had been
minimised. The additional 'shadow' bands of smaller prod-
ucts routinely seen with this technique (Litt, 1991) did not
hamper interpretation of results. Representative findings for
one tumour-normal pair are shown in Figure 2. All results
were scrutinised for evidence of microsatellite mutation
(Thibodeau et al., 1993). Only two examples were identified,
each affecting a single locus (Figure 3).
Only two tumours (tumours 23 and 39) showed no
evidence of deletion at any locus, whereas tumour 8 had
allele loss affecting 65% of informative chromosomal arms.
The mean allele loss per tumour was 28% (s.d. 22.8%).
Because the material studied was derived predominantly from
poorly differentiated serous stage III tumours, it was not
possible to explore the relationship between frequency of
allele loss and parameters such as tumour histology, grade or
stage.
Frequency of loss of heterozygosity for individual
chromosomal arms varied between 0% (16p) and 64% (17q).
Forty per cent or more of informative tumours showed loss
of heterozygosity at chromosomal arms Sq (40%), 9q (48%),
lIp (43%), 14q (46%), 15q (40%), 17p (61%), 17q (64%),
l9p (45%) or Xp (40%). There was a significant relationship
between allele loss affecting the short arm of chromosome 17
and allele loss affecting 17q (P<0.001). Non-disjunction is a
possible explanation for this association. No other relation-
ship was detected between allele losses at different sites in this
cohort of tumours. Although allele loss usually affected all
loci examined for a particular chromosomal arm, there were
notable exceptions. For 9q and 14q partial loss of the arm
was more common than loss of heterozygosity for all loci.
This observation may explain the discrepancy between these
results and those obtained in an earlier allelotyping study
(Sato et al., 1991) in which fewer loci were studied.
Discussion
This paper describes the use of a set of microsatellite
polymorphisms which permits a comprehensive evaluation of
the numerous deletions which may occur throughout the
genome of tumours. The MSPs selected are easy to use,
particularly since the vast majority share common PCR con-
ditions. The use of silver staining or automated sequencing
techniques (Cawkwell et al., 1993) to detect products are
possible refinements which will further increase the utility of
the method.
This approach depends upon the assumption that
chromosome deletions are sufficiently large to allow their
detection using probes which examine only a small number
of loci per arm. Mapping studies employing large numbers of
probes for a particular chromosome reveal that the majority
of deletions are extensive, usually involving an entire arm
(Jacobs et al., 1993; Foulkes et al., 1993a). Small interstitial
or terminal deletions are relatively uncommon. In the present434 R.J. OSBORNE & V. LEECH
Table IV Summary of results for individual chromosomal arms
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Allelotyping results for all loci studied on a chromosomal arm are amalgamated to indicate the frequency with which individual arms are
affected. When loss of heterozygosity is found at one locus on an arm, with retention of heterozygosity at another locus on that arm, the
overall result is scored as loss ofheterozygosity. The symbols used are explained in the key to Table III. The percentage of chromosomal arms
affected by allele loss in individual tumours is listed at the bottom of the table.PCR ALLELOTYPING OF HUMAN OVARIAN CANCER 435
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Figure 1 Percentage loss of heterozygosity on individual chromosomal arms.
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Figure 2 Autoradiographs ofmicrosatellite polymorphism PCR products separated by polyacrylamide gel electrophoresis, showing
examples of allele loss found in tumour no. 52. Left lane, normal lymphocyte DNA; right lane, tumour DNA; R, retention of
heterozygosity; L, loss of heterozygosity.
study examination of only two loci on both 17p and 17q
detected rates of allele loss for both chromosome arms which
were almost identical to those expected from previous studies
(Okamoto et al., 1991; Eccles et al., 1992; Gallion et al.,
1992; Jacobs et al., 1993). These observations support the
validity of using a small number of MSPs per chromosomal
arm. Optimum density of MSPs should take into account the
relative sizes of the chromosomes, but compromises are
forced by the limited number of accurately localised highly
informative probes for some arms. In this study efforts were
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made to achieve even coverage of the genome with the
materials available. With the rapid expansion in numbers of
MSPs, even greater probe density is now feasible.
In the tumours studied, a considerable level of genetic
damage was evident, particularly affecting 5q, 9q, lip, 14q,
15q, 17p, 17q, l9p and Xp. The high rate of allele loss for
17p and 17q is in keeping with results from previous studies
(Okamoto et al., 1991; Eccles et al., 1992; Gallion et al.,
1992; Jacobs et al., 1993). Similar frequencies of allele loss to
those observed here have been reported for lp (Zheng et al.,
1991; Gallion et al., 1992; Viel et al., 1992) and Xp (Yang-
Feng et al., 1992) in ovarian cancer, for 5q in colon cancer
(Solomon et al., 1987) and for 9q in urothelial cancer (Tsai et
al., 1990). Rearrangement of the short arm of chromosome
19 has been consistently observed in ovarian cancer (Pejovic
et al., 1989). Until recently, the long arms of chromosomes
14 and 15 have only been the subject of a limited examina-
tion (Sato et al., 1991) in ovarian cancer, which did not
detect frequent allele loss. However, a more extensive RFLP-
allelotyping study (Cliby et al., 1993) has cast more light on
all the areas mentioned above, with 14q and 15q allele loss
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Figure 3 Microsatellite mutations observed in two tumours, one
at the DIOS173 locus and one at the D16S265 locus. N, normal
lymphocyte DNA; T, tumour DNA; ai, allelle 1; aii, allele 2; M,
mutant alleles.
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being found in 47% and 36% of tumours respectively.
Overall, considerable similarities are evident when the results
from the present study and the allelotyping study based on
RFLP analysis are compared (Figure 4). The discrepancies
observed may result from the relatively small numbers of
tumours studied or the inclusion of low-grade tumours in the
RFLP study, or may be due to differences in the distribution
of the probes employed. This last possibility is unlikely, since
the regions of the chromosomes examined in the instances
where greatest differences were evident were common to both
studies.
Although this study was not performed with the intention
of achieving genotypic-phenotypic correlations, the genetic
abnormalities revealed are likely to prove clinically relevant.
Firstly, the high frequency of allele loss affecting the long
arms of chromosomes 9 and 14 is a new finding in ovarian
cancer, and strongly suggests that these are the sites of as yet
uncharacterised tumour-suppressor genes. This supposition is
supported by the recent observation of frequent 9q deletion
in urothelial malignancy (Tsai et al., 1990) and lymphoma
(Offit et al., 1993). The high incidence ofpartial loss of 9q in
the tumours in this study permits initial localisation of a
smallest region of the overlap of the deletions (R.J. Osborne
et al., in preparation).
Secondly, a surprisingly high overall prevalence of LOH
was observed, with 29/41 arms showing deletion in more
than 20% of informative tumours (mean percentage
LOH = 28%). Similar results (mean percentage LOH = 35%)
have been reported recently (Cliby et al., 1993) in ovarian
cancer. The high rate of allele loss in this disease contrasts
with that reported in endometrial cancer (< 10%) (Fujino et
al., 1993), suggesting that tumours derived from different
tissues, which presumably have different pathogenesis, differ
in the extent of genetic damage which accumulates during
tumour progression.
Finally, this study reveals that microsatellite mutations
(Aaltonen et al., 1993) are very rare in ovarian cancer. Only
two mutations were observed in 25 tumours examined with
68 MSPs (total 1,700 experiments). This finding distinguishes
ovarian cancer from colon cancer in terms of the genetic
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Figure 4 Comparison of allele loss frequencies observed on individual chromosomal arms in the present study (-) and in a
previous RFLP-based allelotyping study (0) (Cliby et al., 1993).PCR ALLELOTYPING OF HUMAN OVARIAN CANCER 437
lesions involved in tumorigenesis, since 28% of sporadic
colon tumours showed microsatellite instability in a recent
study (Thibodeau et al., 1993). The possibility that genetic
dysfunction leading to microsatellite mutation is involved in
some forms of hereditary ovarian cancer has not yet been
explored, since the tumours studied here were all derived
from sporadic cases.
The use of PCR allelotyping to detect the multiple dele-
tions which represent dysfunction of tumour-suppressor
genes is applicable to all tumour types (assuming tissue free
from excessive normal cell contamination can be obtained).
Analysis of a representative panel of tumours with well-
characterised clinical or pathological features will permit cor-
relations between genetic and phenotypic parameters which
are more wide-ranging and complete than those based on
examination of a very limited number of genetic lesions in
tumours, as was previously done. Detailed studies of tumour
progression, using very small amounts of microdissected tis-
sue or archival (formalin fixed, wax embedded) material
(Greer et al., 1991), are possible with this technique.
Examination of epithelium from benign cysts and borderline
tumours which sometimes occur synchronously with frankly
malignant ovarian neoplasms will greatly clarify understan-
ding of the pathogenesis of ovarian cancer. Concurrent
examination of malignant epithelium and underlying stroma
will be similarly important.
Although PCR allelotyping is capable to revealing losses of
genetic material in tumours, it is unsuitable for detection of
gene amplifications and thus the technique may not provide a
full picture of the genetic disturbances in a particular
tumour. It is also unable to detect point mutations or rear-
rangements, and small deletions may also be missed. The
newly developed technique of comparative genomic hybridi-
sation (CGH) (Kallioniemi et al., 1992) is capable of detec-
ting both amplification and deletion of genetic material
affecting any part of any chromosome. Although this app-
roach therefore offers some advantages over PCR allelotyp-
ing, the two methods are probably complementary. PCR
allelotyping provides information about microsatellite ins-
tability and, if necessary, can be applied to map sites of
interest identified by CGH, using increased numbers of
MSPs.
In conclusion, we have compiled and validated a set of
MSPs for detecting deletions on all chromosomes in a simple
and rapid fashion. Use of this approach will not only in-
crease understanding of the relationship between genetic
lesions and clinical behaviour for particular tumour types,
but will also reveal similarities and differences between neo-
plasms derived from histologically distinct tissues.
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